In COVID-19 clinical update #54, Daniel Griffin covers effectiveness of 3 vs 6 ft physical distancing, effectiveness of masks, physical distancing, and eye shields, second vaccine dose completion, alleviation of COVID-19 symptoms after vaccination, vaccine trials in children, and IDSA approval of a mAb cocktail.

On a TWiV tetramer, we review the ongoing outbreaks of Ebolavirus disease in DRC and Guinea, evidence that SARS-CoV-2 infections in children are far more prevalent than are being detected, and recent long COVID estimates from the UK.

In COVID-19 clinical update #53, Daniel Griffin reviews underreporting of infections and long term disease in children, a blood test for T cells, results of phase 3 trials for monoclonal antibodies, preliminary findings on an oral antiviral, clinical trial of ivermectin, and recommendations for upcoming gatherings.

In COVID-19 clinical update #52, Daniel Griffin reviews differences in attack rates between children and adults, J&J vaccine phase III data, G6PD deficiency and vaccines, NIH halts convalescent plasma trial, dexamethasone in hospitalized patients, data on tocilizumab, and long COVID in children.

Theodora and Paul return to TWiV to explain how they quickly pivoted their retrovirus laboratories towards SARS-CoV-2, their work on the antibody response to infection and its durability, and the emergence of variants with increased resistance to neutralization.